Table 1 Performance of different methods in cross-validation experiments.

From: Prioritization Of Nonsynonymous Single Nucleotide Variants For Exome Sequencing Studies Via Integrative Learning On Multiple Genomic Data

 

Neutral

Disease

Combined

MRR(%)

AUC(%)

MRR(%)

AUC(%)

MRR(%)

AUC(%)

eXtasy

7.77

92.20

43.48

56.50

25.87

74.12

SPRING

4.15

95.82

17.25

82.72

10.79

89.20

snvForest†

3.26

96.71

16.02

83.96

9.64

90.34

snvForest‡

3.37

96.60

15.97

84.00

9.76

90.23

  1. †Results for the 19,742 variants extracted from the Swiss-Prot database.
  2. ‡Results for the 25,559 variants that eXtasy covers.
Back to article page